EMA Authorised: Xaluprine (previously Mercaptopurine Nova Laboratories) (6-mercaptopurine monohydrate) — Lipomed GmbH

View source ↗

Summary

EMA authorised Xaluprine (6-mercaptopurine monohydrate) by Lipomed GmbH for leukemia/lymphoid indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• Xaluprine (6-mercaptopurine monohydrate)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Lymphoid. MAH: Lipomed GmbH. Decision date: 24/09/2025